Stock comparison
Halozyme Therapeutics
Tenet Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
THC
Tenet Healthcare
Market cap
$14.97B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | THC | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 55C | HALO |
| Benjamin Graham | 83A | 73B | HALO |
| Philip Fisher | 65B | 47D | HALO |
| Peter Lynch | 53D | 41D | HALO |
| Joel Greenblatt | 40D | 32F | HALO |
| Charlie Munger | 80C | 50D | HALO |
| Terry Smith | 84A | 52D | HALO |
Side-by-side metrics
| Metric | HALO | THC |
|---|---|---|
| Market cap | $8.1B | $14.97B |
| P/E (TTM) | 24.0x | 9.8x |
| EV/EBIT | 10.2x | 7.8x |
| ROIC (TTM) | 23.65% | 11.53% |
| Gross margin | 81.24% | 42.76% |
| Net margin | 23.13% | 7.94% |
| Revenue CAGR 5y | 33.23% | 2.26% |
| EPS CAGR 5y | -1.98% | 16.24% |
| Debt / Equity | 1.0x | 2.7x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs 2.26%+93%
- Net margin23.13%vs 7.94%+66%
- Debt / Equity1.0xvs 2.7x+65%
- ROIC (TTM)23.65%vs 11.53%+51%
THC leads on
- EPS CAGR 5y16.24%vs -1.98%+112%
- P/E (TTM)9.8xvs 24.0x+59%
- Market cap$14.97Bvs $8.1B+46%
- EV/EBIT7.8xvs 10.2x+24%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.